Stay updated with breaking news from Cullinan pearl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Taiho licensed the drug to Cullinan in 2019 but has now acquired Cullinan subsidiary Cullinan Pearl to resume codevelopment and commercialization of the program. ....
Humacyte (NASDAQ:HUMA – Get Rating) and Cullinan Oncology (NASDAQ:CGEM – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk. Profitability This table compares Humacyte and Cullinan Oncology’s net margins, […] ....
Midway through trading Friday, the Dow traded up 0.39% to 34,713.33 while the NASDAQ rose 1.28% to 13,789.21. The S&P also rose, gaining 0.69% to . ....
Cullinan Oncology Reports Full Year 2020 Financial Results and Business Highlights globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for . Zai Lab LimitedDecember 28, 2020 GMT - Zai Lab to lead development and commercialization of CLN-081 in Greater China - Cullinan will receive $20 million upfront, up to $211 million in future milestones, and royalties - Zai Lab to join ongoing global trial for CLN-081 SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 28, 2020 (GLOBE NEWSWIRE) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and Cullinan Oncology, a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, today announced an exclusive license agreement for the development, manufacturing and commercialization of CLN-081 in Greater China. ....